Endothelial progenitor cells (EPCs) play a role in angiogenesis during pregnancy. The aim of this study was to evaluate circulating EPCs in pregnant women with gestational alterations of glucose tolerance. Glucose tolerance, insulin sensitivity and β-cell function were derived from oral glucose tolerance tests in 23 women with normal glucose tolerance (NGT), 18 with gestational impaired glucose tolerance (GIGT) and 24 with gestational diabetes mellitus (GDM). Circulating cells expressing CD34 in combination with CD133, kinase insert domain receptor (KDR) or both were quantified by flow cytometry. Women with GIGT and GDM had lower CD34 + KDR + and CD34 + CD133 + KDR + cells at 27±3.2 weeks' gestation compared with NGT (ANOVA p<0.02 for both). CD34 + KDR + and CD34 + CD133 + KDR + cells were inversely correlated with the area-under-the-glucose-curve (p<0.005, for both) and positively to insulin secretion-sensitivity index (p<0.05, for both). Alterations of glucose tolerance during pregnancy are associated with a decrease in EPCs. Hyperglycaemia might exert a direct effect on depletion of EPCs.
Introduction
Bone marrow-derived endothelial progenitor cells (EPCs) contribute to maintain vascular integrity by generating new endothelial cells and by activating neo-angiogenic processes. 1 Alterations in both number and function of EPCs have been reported in cardiovascular disorders. 2 Furthermore, risk factors for coronary artery disease 3 as well as type 2 diabetes mellitus 4, 5 are associated with reduced availability and function of EPCs. Recently we have demonstrated that also non-diabetic hyperglycaemia is negatively associated with the number of circulating EPCs. 6 EPCs are believed to contribute to the development, regulation and maintenance of systemic and utero-placental vasculature during physiological pregnancy, a condition where cardiovascular adaptation occurs to sustain the development of the foetus. 7 During normal pregnancy, endothelial function and reactivity are enhanced from the first to the last trimester, as indicated by increased endotheliumdependent flow-mediated vasodilation of the brachial artery. 8 In contrast, little is known about circulating EPCs during normal pregnancy. Gussin et al. 9 and Sugawara et al. 10 reported that normal pregnancy is associated with mobilisation of EPCs into the circulation, 9 with an increasing number of colony-forming units as a function of gestational age and serum estradiol levels. 10 A progressive increase with gestational age in the concentration of EPCs during pregnancy in healthy women was also observed by Buemi et al. 11 Opposite results were found by Matsubara et al. 12 and Savvidou et al., 13 showing that normal singleton and twin pregnancies were associated with a trend of decreasing levels of maternal circulating EPCs with advancing gestation as compared with non-pregnant controls.
Common complications of pregnancy such as preeclampsia and gestational diabetes are associated with systemic maternal endothelial dysfunction, 7, 14 while data on
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EPCs in those conditions are scanty and conflicting. 7, 15 A reduction in the number and acceleration in senescence of EPCs have been reported in pregnant women with preeclampsia 16, 17 and in those with hypertension disorder complicating pregnancy. 18 These alterations have been associated with endothelial dysfunction and systemic inflammation, 16 although those findings have not been universally confirmed. 11, 12 Gestational diabetes is associated with an increased risk of pre-eclampsia. Yet, only a few studies, to the best of our knowledge, have evaluated the number of circulating EPCs during the third trimester of pregnancy in women with gestational diabetes. 11, 19 We now report results of a study designed to examine the number of circulating EPCs in otherwise healthy pregnant women with different degrees of glucose tolerance.
Materials and methods

Study subjects
The study was performed according to the guidelines of the Fifth International Workshop-Conference on Gestational Diabetes Mellitus. 20 A total of 65 pregnant women were recruited at the Diabetes and Metabolic Unit of the University Hospital of Pisa using a sequential model of universal screening based on a 50 g 1 h glucose challenge test (GCT), followed by a diagnostic 100 g 3 h oral glucose tolerance test (OGTT) in women with a positive screening test. 21 Thus, all women recruited had plasma glucose values ≥7.7 mmol/l 1 h after the standard 50 g glucose load. The Institutional Review Board of the Pisa University School of Medicine approved the protocol; informed consent was obtained from all women. Exclusion criteria were type 1 or type 2 diabetes, illness affecting glucose metabolism such as polycystic ovarian syndrome, treatments with agents that affect glucose metabolism, multiple gestation, cardiovascular disease and, in particular, history of pre-eclampsia in the current or previous gestations. All women were studied after 12 h overnight fasting. On the morning of the test, after collection of demographic, anthropometric, and clinical data (age, family history of diabetes, obstetric history, and body mass index (BMI)) a baseline blood sample was obtained for quantification of circulating EPCs and determination of fasting plasma glucose and insulin concentrations. Upon collection of the baseline sample, a 100 g OGTT was performed and blood samples taken at 60 min interval for the ensuing 3 h for the determination of plasma glucose and insulin concentration. All tests were performed at 27±3.2 weeks of gestation. Based on the OGTT, participants were stratified into three glucose tolerance categories: 
Measurements and calculations
Plasma glucose levels were determined on a Beckman Glucose Analyzer 2 (Beckman Fullerton, CA, USA) by the glucose oxidase method, and plasma insulin concentration by radioimmunoassay (INSI-CTK Irma; DiaSorin, Vercelli, Italy). The intra-and inter-assay coefficients of variation for both parameters were <5%. Incremental area under the curve (AUC) for plasma glucose (AUC gluc ) and insulin (AUC ins ) during OGTT were calculated using the trapezoidal rule. Insulin sensitivity was calculated as ISIcomp (Matsuda and DeFronzo index) and OGIS (oral glucose insulin sensitivity index) after OGTT, 22 while first-phase insulin secretion was calculated according to Stumvoll et al. 23 The product of the ISI and the Stumvoll first-phase index of insulin secretion was calculated to obtain the insulin secretion-sensitivity index (ISSI). This index, which relates β-cell function to the ambient insulin sensitivity, has been previously used in pregnant women. 24, 25 
Quantification of circulating EPCs
A venous blood sample was collected into EDTA tubes and stored at room temperature until complete processing (within 2 h). Different sub-populations were identified using the hematopoietic progenitor cell marker CD34, the immature hematopoietic progenitor cell marker CD133, and the endothelial cell receptor VEGFR-2 (vascular endothelial growth factor receptor-2 or kinase insert domain receptor, KDR) as described previously. 6 Briefly, 100 µl blood was incubated with 10 µl PerCP-conjugated anti-human CD34 monoclonal antibody (mAb; Becton-Dickinson Biosciences), 10 µl phycoerythrin (PE)conjugated anti-human CD133 mAb (Miltenyi Biotec, Bergisch Gladbach, Germany) and 10 µl allophycocyaninconjugated anti-human KDR mAb (R&D Systems, Wiesbaden-Nordenstadt, Germany) for 30 min at 4°C. The cytometer (FACScan, Becton-Dickinson Biosciences) acquired at least 5×10 5 events. The frequency of peripheral blood cells positive for these reagents was determined by a two-dimensional fluorescence dot-plot analysis of the samples, after appropriate gating. We initially gated CD34+ peripheral blood cells in the mononuclear cell fraction and then examined the resulting population for expression of KDR, CD133 or both ( Figure 1 ). Data were processed using a software program (Macintosh Cell Quest, BD Bioscience). Cell counts were expressed as number of cells per 10 6 cytometric events. The operator carrying out all tests was blinded to the clinical status of participants.
Statistical analysis
Sample size was calculated against EPCs count for analysis of variance (ANOVA) comparison. With an anticipated within-group standard deviation (SD) for EPCs (assumed as homogeneous between groups) of 25%, an anticipated minimal detectable difference among the three groups of pregnant women of 30%, and a 0.5 controls to experimental subjects ratio, 20 cases per group were required for a twotailed alpha of 0.05 and a 10% risk of type 2 error. Data are Figure 1 . Representative flow cytometry scatter plots used to determine CD34 + KDR + CD133 + cell counts. After morphological gating in the mononuclear cell fraction (A), CD34 + cells were identified using an anti-CD34 mAb (B); CD34 + KDR + CD133 + cells were then identified in the CD34 + gate using anti-KDR and anti-CD133 mAbs (C). 
Results
Characteristics of the study population
A total of 65 Caucasian pregnant women with a positive GCT underwent a 100 g 3 h diagnostic OGTT leading to identification of 24 GDM, 18 GIGT, and 23 NGT women. The main clinical features of the three groups are summarised in Table 1 . GDM, GIGT and NGT women were comparable for age, family history of diabetes, pre-pregnancy body weight, BMI, incremental gestational body weight and blood pressure levels. All subjects were not on prescribed medication. No woman was currently smoking, while percent of women who were tobacco smokers before pregnancy was similar in the three groups.
There was no difference in plasma insulin concentration during OGTT with the exception of higher levels at 120 min of the OGTT in GIGT and GDM women as compared with NGT (p=0.01). As expected both AUC gluc (p<0.0001) and AUC ins (p=0.06) increased across the three glucose tolerance categories.
Similarly, ISIcomp and OGIS showed a progressive reduction from women with NGT to those with GIGT and GDM (ISIcomp: 4.92±2.05, 4.43±2.68, and 3.35±1.87, respectively, p<0.05; OGIS 387±53, 357±70, and 316±79 mg/min/m 2 , respectively, p<0.005). ISSI index was higher (p<0.0001) in women with NGT compared with GIGT and GDM (Table 1) .
Circulating progenitor cells in women with glucose metabolism abnormalities
While counting of circulating CD34 + cells (NGT: 353.7±165.9; GIGT: 417.2±242.5; GDM: 423.3±220.0 cells/ 10 6 events) and CD34 + CD133 + cells (NGT: 314.1±165.9; GIGT: 272.0±157.4; GDM: 287.9±152.8 cells/10 6 events) was similar in the three groups, the number of circulating EPCs (i.e. CD34 + KDR + and CD34 + CD133 + KDR + cells) was different (p<0.02, for both). In particular, the number of circulating CD34 + KDR + and CD34 + CD133 + KDR + cells was higher in NGT (60.8±59.6 and 55.6±57.9 cells/10 6 events, respectively) as compared with both GIGT (30.8±21.6 and 26.6±19.66 cells/10 6 events, respectively; p=0.020/0.018), and GDM (30.2±22.3 and 26.5±20.5 cells/10 6 events, respectively; p=0.010/0.011), with no differences between GIGT and GDM ( Figure 2 ). Accordingly, EPCs levels were higher in the 23 NGT women than in the 42 women with GIGT or GDM (CD34 + KDR + : 60.8±59.6 vs. 30.5±21.8 cells/10 6 events, respectively, p=0.004; CD34 + CD133 + KDR + : 55.6±57.8 vs. 26.5±19.9 cells/10 6 events, respectively; p=0.004).
The natural ln-transformed count of circulating CD34 + CD133 + KDR + cells was inversely correlated with age (r=−0.26, p=0.04), but not with BMI, weight gain during pregnancy or blood pressure levels. EPCs count was inversely related with 1 h (r=−0.30, p<0.02) and 2 h postload plasma glucose (r=−0.36, p<0.005) as well as AUC gluc (r=−0.37, p<0.005) (Figure 3 ). No correlation was found with plasma insulin levels or AUC ins . A weak positive correlation ( Figure 3 ) was apparent between EPC counting and ISSI (r=0.25, p<0.05) . Finally, no associations were apparent between EPCs count and post-OGTT insulin sensitivity indexes (ISIcomp: r=0.01, p=0.95; OGIS: r=0.15, p=0.24) . Similar results (data not shown) were observed for CD34 + KDR + cells.
When all parameters (age, 1 h and 2 h post-load plasma glucose, AUC gluc , and ISSI) that were significantly correlated with CD34 + CD133 + KDR + cells count as well as insulin sensitivity parameters were entered in a multiple linear regression model, only age (r=−0.26, p=0.021) and AUC gluc (p=0.027) remained significantly associated with EPCs count (multiple r=−0.45, p=0.003). Similar results (data not shown) were observed for CD34 + KDR + cells.
Discussion
This study demonstrates that the numbers of circulating CD34 + KDR + and CD34 + CD133 + KDR + EPCs are significantly reduced in late stage of pregnancy in women with alterations of their glucose metabolism. Of interest, the reduction in the number of these subsets of circulating EPCs seems to be already fully apparent for modest alterations of glucose homeostasis, since no difference was observed between women with GIGT as compared with those with GDM. This finding is in keeping with our previous observations showing that pre-diabetic individuals (subjects with impaired fasting glucose or impaired glucose tolerance) also have a reduction in circulating EPCs. 6 This is also in keeping with the time course of circulating progenitor cell reduction in the progression of the natural history of type 2 diabetes. 4 While the low number of EPCs is apparent, the mechanisms responsible for such a reduction is less clear. A drop in EPCs count may result from defective bone marrow release or increased apoptosis as well as increased utilisation in the peripheral circulation. The latter could be consistent with the dramatic remodelling that the uterine vasculature undergoes during pregnancy. 7, 15, 26 In agreement with this interpretation is the reduction in maternal circulating EPCs in pregnant as compared with non-pregnant women previously reported. 12, 13 However, the much lower EPC count in pregnant women with impaired glucose tolerance supports an independent metabolic effect and, therefore, the potential implication in increasing vascular risk. With respect to this, it is of interest to note that women with gestational diabetes have endothelial dysfunction, 27 while defects in vascular function 28 and higher intima-media thickness 29 have been reported in women with previous gestational diabetes. Furthermore, a higher risk of cardiovascular disease has been reported both in women with previous gestational diabetes 30, 31 as well in those with mild glucose intolerance during pregnancy. 31 Finally, gestational diabetes has been associated with vascular complications during pregnancy. For instance, pre-eclampsia occurs more commonly in women with altered glucose metabolism, 32 and a significant reduction in maternal EPC number 33 and colony-forming units 17 have been reported in pre-eclampsia.
The reduction of circulating EPCs is likely to be directly related to elevation of plasma glucose levels because there was no association with BMI, body weight gain during pregnancy, or blood pressure, while both 1 h and 2 h plasma glucose as well as the AUC glucose were related to the circulating number of EPCs, with the latter remaining significantly and independently associated, together with age, with EPCs count in a multiple regression analysis. These two variables (age and glucose tolerance), although potentially associated, really seem to play an independent effect because no age difference was apparent in our study among women with normal, impaired or diabetic glucose tolerance ( Table 1) .
Elevation of plasma glucose levels may contribute to reducing circulating EPCs by acting on both their production and removal from the circulation. Several experimental findings suggest a link between glucose toxicity and progenitor cell alterations. In vitro, mild hyperglycaemia has been shown to impair proliferation, function, and survival of cultured blood-derived progenitor cells 34 as well as circulating EPCs. 35, 36 In a recent report, the inhibitory effect of high glucose alone on EPCs proliferation was even stronger than that of high glucose plus high insulin, with no effect exerted by high insulin alone. 37 Uncoupling endothelial nitric oxide synthase (eNOS) and reduced nitric oxide (NO) bioavailability, mechanistically linked to a reduced intracellular BH 4 cofactor (tetrahydrobiopterin) concentration, has been demonstrated in EPCs from diabetic patients and in EPCs exposed to high glucose concentration. 35, 36 Furthermore, elevation in glucose levels increases production of reactive oxygen species (ROS) resulting in higher 3-nitrotyrosine levels. While EPCs are equipped with powerful antioxidant enzyme systems, 38 the damaging effects of ROS cannot be efficiently counteracted under hyperglycaemia due to eNOS uncoupling. 36 NO donor, 39 but not antioxidants, can reverse impaired proliferation and function of circulating EPCs, suggesting the prevalence of NO-related rather than oxidative stress-mediated mechanisms in hyperglycaemia-induced EPC down-regulation. 35 Finally, accumulation of advanced glycation end products may contribute to EPCs dysfunction through effects on protein kinase Akt and cyclooxygenase-2. 40 The same processes may contribute to endothelial damage causing increased homing of circulating EPCs.
Moderate hyperglycaemia may also contribute to sustain chronic inflammation, another factor that may affect circulating EPCs. 41 During pregnancy biologically active cytokines are synthesised and released by the placenta, the adipose tissue, and the skeletal muscle. 42 Furthermore, experimental data have shown that the release of tumour necrosis factor-alpha (TNF-α) by placental and adipose tissue obtained from women with gestational diabetes is enhanced by hyperglycaemia. 43 Subclinical inflammation is often associated with insulin resistance, suggesting the latter too might contribute to the reduction of EPC numbers. Although it may be difficult to dissect out the contribution of insulin resistance from that of mild alteration of glucose tolerance, and even though a multiple regression analysis on a small sample size may not be robust, our data suggest that an independent role of insulin resistance is unlikely since no association was found between the number of EPCs and estimates of fasting or post-OGTT insulin sensitivity.
Some limitations of our study are worth considering. In spite of different levels of glucose tolerance, the three groups of women were not different with respect to other features. Therefore, while this may be seen as an advantage, we cannot exclude that a larger sample size might have revealed the role of other potential interfering factors. In spite of correlations and multiple regression analysis supporting a role for glucose intolerance in reducing EPC, no cause-effect relationship can be confirmed. This would require a longitudinal rather than a cross-sectional study as the present one. However, collecting sufficient number of women developing different degrees of glucose tolerance during pregnancy may not be an easy task. The only report that has looked at changes in the number of circulating EPCs during pregnancy has been limited to a very small number (n=7) normotolerant women. 11 Finally, one should keep in mind that only women with an altered 50 g glucose load were recruited for subsequent OGTT, so that results obtained in NGT women may not necessarily reflect those that may be obtained in women with normal 50 g glucose load.
Finally, a further limitation relies on the lack of consensus regarding the identity of EPCs on the basis of surface antigens or any other criteria. 44 There is evidence that EPCs are so heterogeneous that our data might not apply to all endothelial (or circulating angiogenic) progenitor cell populations. CD34 + cell subsets (i.e. CD34 + KDR + or CD34 + CD133 + KDR + ) are far from being the 'gold standard' identifiers of an EPC. However, it is a point of strength that circulating CD34 + CD133 + KDR + cells have been touted as representing a distinct population with a role in neo-angiogenesis. 45 Nevertheless, CD34, CD133 and KDR are shared by hematopoietic precursors that can mobilise and home to injured sites, contributing to vessel homeostasis and repair in an indirect manner. 44 Furthermore, it is of interest to observe that endothelial colony-forming cells, thought to be the only EPC subtype contributing structurally to neovessels, are distinctly CD133-negative. 44 In the recent study by Acosta et al., 19 women with GDM have fewer circulating progenitor cells identified as the CD34 + CD133 + CD45 + CD31 + phenotype at 24-32 weeks' gestation compared with control subjects. Such results may be of some help in more appropriately framing our findings in the context of EPCs heterogeneity and the apparently conflicting results in the literature regarding changes in EPCs in normal pregnancy. [9] [10] [11] [12] [13] In conclusion, we have shown that mild alteration in glucose tolerance during pregnancy is associated with a reduction in the number of circulating EPCs. This finding together with the reported alterations in multiple cardiovascular risk factors previously observed in women with gestational diabetes emphasises the need for careful follow-up in all women with even modest alterations in glucose tolerance. Further studies will be needed to assess whether measuring EPCs develops into a clinically useful test to assess risk during or beyond pregnancy, and to explore the possibility that reduction in circulating EPCs may contribute to vascular complications during pregnancy such as pre-eclampsia.
